Type I DNA topoisomerase from protozoan pathogens as a potential target for anti-tumoral drugs;La ADN topoisomerasa tipo i de protozoos patogenos como diana terapeutica de farmacos antitumorales

Medicina

Volumn 67, Issue 6 II, 2007, Pages 747-757

  Reguera, Rosa M ^a   Perez Pertejo, Yolanda ^a   Redondo, Carmen M ^a   Diaz Gonzalez, Rosario ^a   Balaña Fouce, Rafael ^a  

^a UNIVERSITY OF LEÓN   (Spain)

Author keywords

Camptothecin; DNA topology; Tropical diseases; Type I DNA topoisomerase

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; ARGININE; ASPARAGINE; CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; HO 33258; HO 33342; LYSINE; MEGLUMINE ANTIMONATE; MILTEFOSINE; STIBOGLUCONATE SODIUM; TYROSINE; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; AMINO ACID SEQUENCE; CHAGAS DISEASE; CHEMOTHERAPY; CRYPTOSPORIDIOSIS; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; ENVIRONMENTAL SANITATION; ENZYME LOCALIZATION; LEISHMANIASIS; MALARIA; MOSQUITO; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE VIRULENCE; PATHOGENESIS; PROTEIN INTERACTION; PROTOZOON; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; TRYPANOSOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DRUG DESIGN; HUMANS; LEISHMANIA; NEOPLASMS; PROTOZOA; PROTOZOAN INFECTIONS; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOSOMA;

EID: 38449107946     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Greenwood BM, Bojang K, Whitty CJM, Targett GAT. Malaria. Lancet 2005; 365: 1487-98.
2. Shlomai J. The structure and replication of kinetoplast DNA. Curr Mol Med 2004; 4: 623-47.
3. Kioy D, Jannin J, Mattock N. Human African trypanosomiasis. Nat Rev Microbiol 2004; 2: 186-7.
4. Miles MA, Feliciangeli MD, de Arias AR. American trypanosomiasis (Chagas' disease) and the role of molecular epidemiology in guiding control strategies. BMJ 2003; 326: 1444-8.
5. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27:305-8
6. May J, Meyer CG. Chemoresistance in falciparum malaria. Trends Parasitol 2003 19; 432-5.
7. Le Bras J, Durand R. The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum. Fundam Clin Pharmacol 2003; 17: 147-53.
8. Ashley EA, White NJ. Artemisinin-based combinations. Curr Opin Infect Dis 2005; 18: 531-6.
9. Legros D, Ollivier G, Gastellu-Etchegorry M, Paquet C, Burri C, Jannin J, et al. Treatment of human African trypanosomiasis-present situation and needs for research and development. Lancet Infect Dis 2002; 2: 437-40.
10. Kennedy PG. Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest 2004; 113: 496-504.
11. Mpia B, Pepin J. Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis. Trop Med Int Health 2002; 7: 775-9.
12. Urbina JA, Docampo R. Specific chemotherapy of Chagas' disease: controversies and advances. Trends Parasitol 2003: 19; 495-501.
13. Docampo R. Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem Biol Interact 1990; 73: 1-27.
14. Croft SL, Coombs GH. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003; 19: 502-8.
15. Balaña-Fouce R, Reguera RM, Cubría JC, Ordóñez D. The pharmacology of leishmaniasis. Gen Pharmacol 1998; 30: 435-43.
16. Bommer W, Eibl HJ, Engel KR, Kuhlencord A, Sindermann H, Sundar S, et al. Leishmaniasis - oral treatment with hexadecylphosphocholine. Wien Klin Wochenschr 2004; 116: 24-9.
17. Rivas L, Moreno J, Cañavate C, Alvar J. Virulence and disease in leishmaniasis: what is relevant for the patient? Trends Parasitol 2004; 20: 297-301.
18. Harms G, Feldmeier H. The impact of HIV infection on tropical diseases. Infect Dis Clin North Am 2005; 19: 121-35.
19. Burton A. Sharing needles may produce artificial Leishmania cycle. Lancet Infect Dis 2001; 1: 4.
20. Vinograd J, Lebowitz J, Radloff R, Watson R, Laipis P. The twisted circular form of polyoma viral DNA. Proc Natl Acad Sci USA 1965; 53: 1104-11.
21. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001; 70: 369-413.
22. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002; 3: 430-40.
23. Corbett KD, Berger JM. Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu Rev Biophys Biomol Struct 2004; 33: 95-118.
24. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996; 65: 635-92.
25. Cheesman S, McAleese S, Goman M, Johnson D, Horrocks P, Ridley RG, et al. The gene encoding topoisomerase II from Plasmodium falciparum. Nucleic Acids Res 1994; 22: 2547-51.
26. Christopher LJ, Dykstra CC. Identification of a type II topoisomerase gene from Cryptosporidium parvum. J Eukaryot Microbiol 1994; 41: 28S.
27. Strauss PR, Wang JC. The TOP2 gene of Trypanosoma brucei: a single-copy gene that shares extensive homology with other TOP2 genes encoding eukaryotic DNA topoisomerase II. Mol Biochem Parasitol 1990; 38: 141-50.
28. Fragoso SP, Goldenberg S. Cloning and characterization of the gene encoding Trypanosoma cruzi DNA topoisomerase II. Mol Biochem Parasitol 1992; 55: 127-34.
29. Das A, Dasgupta A, Sharma S, Ghosh M, Sengupta T, Bandopadhyay S, et al. Characterization of the gene encoding type II DNA topoisomerase from Leishmania donovani: a key molecular target in antileishmanial therapy. Nucleic Acids Res 2001; 29: 1844-51.
30. Hanke T, Ramiro MJ, Trigueros S, Roca J, Larraga V. Cloning, functional analysis and post-transcriptional regulation of a type II DNA topoisomerase from Leishmania infantum. A new potential target for anti-parasite drugs. Nucleic Acids Res 2003; 31: 4917-28.
31. Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ. A model for the mechanism of human topoisomerase I. Science 1998; 279: 1534-41.
32. Champoux JJ. Domains of human topoisomerase I and associated functions. Prog Nucleic Acids Res Mol Biol 1998; 60: 111-32.
33. Stewart L, Ireton GC, Champoux JJ. The domain organization of DNA topoisomerase I. J Biol Chem 1996; 271: 7602-8.
34. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998; 279: 1504-13.
35. Riou JF, Gabillot M, Philippe M, Schrevel J, Riou G. Purification and characterization of Plasmodium berghei DNA topoisomerases I and II: drug action, inhibition of decatenation and relaxation, and stimulation of DNA cleavage. Biochemistry 1986; 25: 1471-9.
36. Tosh K, Kilbey B. The gene encoding topoisomerase I from the human parasite Plasmodium falciparum. Gene 1995; 163: 151-4.
37. Tosh K, Cheesman S, Horrocks P, Kilbey B. Plasmodium falciparum: stage-related expression of topoisomerase I. Exp Parasitol 1999; 91: 126-32.
38. Villa H, Otero-Marcos AR, Reguera RM, et al. A novel active DNA topoisomerase I in Leishmania donovani. J Biol Chem 2003; 278: 3521-6.
39. Bodley AL, Chakraborty AK, Xie S, Burri C, Shapiro TA. An unusual type IB topoisomerase from African trypanosomes. Proc Natl Acad Sci USA 2003; 100: 7539-44.
40. Das BB, Sen N, Ganguly A, Majumder HK. Reconstitution and functional characterization of the unusual bi-subunit type I DNA topoisomerase from Leishmania donovani. FEBS Lett 2004; 565: 81-8.
41. Wang Z, Englund PT. RNA interference of a trypanosome topoisomerase II causes progressive loss of mitochondrial DNA. EMBO J 2001; 20: 4674-83.
42. Bakshi RP, Shapiro TA. RNA interference of Trypanosoma brucei topoisomerase IB: both subunits are essential. Mol Biochem Parasitol 2004; 136: 249-55.
43. Das A, Dasgupta A, Sengupta T, Majumder HK. Topoisomerases of kinetoplastid parasites as potential chemotherapeutic targets. Trends Parasitol 2004; 20: 381-7.
44. Balaña-Fouce R, Redondo CM, Pérez-Pertejo Y, Díaz-González R, Reguera RM. Targeting atypical trypanosomatid DNA topoisomerase I. Drug Discov Today 2006;11: 733-40.
45. Reguera RM, Redondo CM, Gutiérrez de Prado R, Pérez-Pertejo Y, Balaña-Fouce R. DNA topoisomerase I from parasitic protozoa: a potential target for chemotherapy. Biochim Biophys Acta 2006; 1759: 117-31.
46. Wang JC. DNA topoisomerases as targets of therapeutics: an overview. Adv Pharmacol 1994; 29: 1-19.
47. Capranico G, Giaccone G, Zunino F, Garattini S, D'Incalci M. Development of DNA topoisomerase-related therapeutics: a short perspective of new challenges. Curr Med Chem Anticancer Agents 2004; 4: 335-45.
48. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003; 361: 2235-42.
49. Adams DJ. The impact of tumor physiology on camptothecin-based drug development. Curr Med Chem Anticancer Agents 2005; 5: 1-13.
50. Sriram D, Yogeeswari P, Thirumurugan R, Bal TR. Camptothecin and its analogues: a review on their chemotherapeutic potential. Nat Prod Res 2005; 19: 393-412.
51. Bodley AL, Shapiro TA. Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proc Natl Acad Sci USA 1995; 92: 3726-30.
52. Bodley AL, Cumming JN, Shapiro TA. Effect of camptothecin, a topoisomerase I inhibitor on Plasmodium falciparum. Biochem Pharmacol 1998; 55: 709-11.
53. Bodley AL, Wani MC, Wall ME, Shapiro TA. Antitrypanosomal activity of camptothecin analogs. Structure-activity correlations. Biochem Pharmacol 1995; 50: 937-42.
54. Staker BL, Feese MD, Cushman M, et al. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem 2005; 48: 2336-45.
55. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin Jr AB, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA 2002; 99: 15387-92.
56. Redinbo MR, Champoux JJ, Hol WG. Structural insights into the function of type IB topoisomerases. Curr Opin Struct Biol 1999; 9: 29-36.
57. Lee N, Bertholet S, Debrabant A, Muller J, Duncan R, Nakhasi HL. Programmed cell death in the unicellular protozoan parasite Leishmania. Cell Death Differ 2002; 9: 53-64.
58. Sen N, Das BB, Ganguly A, Mukherjee T, et al. Camptothecin induced mito-chondrial dysfunction leading to programmed cell death in unicellular hemoflagellate Leishmania donovan. Cell Death Differ 2004; 11: 924-36.
59. Sen N, Das BB, Ganguly A, Mukherjee T, Bandyopadhyay S, Majumder HK. Camptothecin-induced imbalance in intracellular cation homeostasis regulates programmed cell death in unicellular hemoflagellate Leishmania donovani. J Biol Chem 2004; 279: 52366-75.
60. Proulx M.E, Desormeaux A, Marquis JF, Olivier M, Bergeron MG. Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin. Antimicrob Agents Chemother 2001; 45: 2623-7.
61. Meng LH, Liao ZY, Pommier Y. Non-camptothecin DNA-topoisomerase I inhibitors in cancer therapy. Curr Top Med Chem 2003; 3: 305-20.
62. Deterding A, Dungey FA, Thompson KA, Steverding D. Anti-trypanosomal activities of DNA topoisomerase inhibitors. Acta Trop 2005; 93: 311-6.
63. Antony S, Kohlhagen G, Agama K, et al. Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison. Mol Phar-macol 2005; 67: 523-30.
64. Hazra B, Saha AK, Ray R, Roy DK, Sur P, Banerjee A. Antiprotozoal activity of diospyrin towards Leishmania donovani promastigotes in vitro. Trans R Soc Trop Med Hyg 1987; 81: 738-41.
65. Ray S, Hazra B, Mittra B, Das A, Majumder HK. Diospyrin, a bisnaphthoquinone: a novel inhibitor of type I DNA topoisomerase of Leishmania donovani. Mol Pharmacol 1998; 54: 994-9.
66. Syrovets T, Buchele B, Gedig E, Slupsky JR, Simmet T. Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and II. Mol Pharmacol 2000; 58: 71-81.
67. Chowdhury AR, Mandal S, Goswami A, et al. Dihydrobetulinic acid induces apoptosis in Leishmania donovani by targeting DNA topoisomerase I and II: implications in anti-leishmanial therapy. Mol Med 2003; 9: 26-36.
68. Vennerstrom J, Lovelace JK, Waits VB, Hanson WL, Klayman DL. Berberine derivatives as antileishmanial drugs. Antimicrob Agents Chemother 1990; 34: 918-21.
69. Marquis JF, Makhey D, LaVoie EJ, Olivier M. Effects of topoisomerases inhibitors protoberberine on Leishmania donovani growth, macrophage function, and infection. J Parasitol 2003; 89: 1048-52.
70. Lucumi A, Robledo S, Gama V, Saravia NG. Sensitivity of Leishmania viannia panamensis to pentavalent antimony is correlated with the formation of cleavable DNA-protein complexes. Antimicrob Agents Chemother 1998; 42: 1990-5.
71. Chakraborty AK, Majumder HK. Mode of action of pentavalent antimonials: specific inhibition of type I DNA topoisomerase of Leishmania donovani. Biochem Biophys Res Commun 1988; 152: 605-11.
72. Walker J, Saravia NG. Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents. J Parasitol 2004; 90: 1155-62.
73. Chen AY, Yu C, Gatto B, Liu LF. DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc Natl Acad Sci USA 1993; 90: 8131-5
74. Jean-Moreno V, Rojas R, Goyeneche D, Coombs GH, Walker J. Leishmania donovani: differential activities of classical topoisomerase inhibitors and antileishmanials against parasite and host cells at the level of DNA topoisomerase I and in cytotoxicity assays. Exp Parasitol 2006; 112: 21-30.
75. Baguley BC, Ferguson LR. Mutagenic properties of topoisomerase-targeted drugs. Biochim Biophys Acta 1998; 1400: 213-22.
76. Pourquier P, Pommier Y. Topoisomerase I-mediated DNA damage. Adv Cancer Res 2001; 80: 189-216.
77. Pommiér Y, Redon C, Rao VA, et al. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res 2003; 532: 173-203.
78. Desai SD, Liu LF, Vazquez-Abad D, D'Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem 1997; 272: 24159-64.
79. Desai SD, Li TK, Rodriguez-Bauman A, Rubin EH, Liu LF. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res 2001; 61: 5926-32.
80. Pommier Y. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints. Curr Med Chem Anticancer Agents 2004; 4: 429-34.
81. Cusack Jr. JC, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systematic nuclear factor-kB inhibition. Cancer Res 2001; 61: 3535-40.
82. Mao Y, Sun M, Desai SD, Liu LF. SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage. Proc Natl Acad Sci USA 2000; 97: 4046-51.
83. Horie K, Tomida A, Sugimoto Y, et al. SUMO-1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin. Oncogene 2002; 21: 7913-22.
84. Mo YY, Yu Y, Shen Z, Beck WT. Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein. J Biol Chem 2002; 277: 2958-64.
85. Emmerlich V, Santarius U, Bakker-Grunwald T, Scholze H. Isolation and subunit composition of the 20S proteasome of Giardia lamblia. Mol Biochem Parasitol 1999; 100: 131-4.
86. Yao Y, Toth CR, Huang L, et al. Alpha5 subunit in Trypanosoma brucei protea-some can self-assemble to form a cylinder of four stacked heptamer rings. Biochem J 1999; 344: 349-58.
87. Diego JL, Katz JM, Marshall P, et al. The ubiquitin-proteasome pathway plays an essential role in proteolysis during Trypanosoma cruzi remodeling. Biochemistry 2001; 40: 1053-62.
88. Robertson CD. The Leishmania mexicana proteasome. Mol Biochem Parasitol 1999; 103: 49-60.
89. Hellberg A, Sommer A, Bruchhaus I. Primary sequence of a putative non-ATPase subunit of the 26S proteasome from Entamoeba histolytica is similar to the human and yeast S2 subunit. Parasitol Res 1999; 85: 417-20.
90. Certad G, Abrahem A, Georges E. Cloning and partial characterization of the proteasome S4 ATPase from Plasmodium falciparum. Exp Parasitol 1999; 93: 123-31.
91. Paugam A, Creuzet C, Dupouy-Camet J, Roisin MP. Evidence for the existence of a proteasome in Toxoplasma gondii. intracellular localization and specific peptidase activities. Parasite 2001; 8: 267-73.